-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community EventCancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
-
Making Clinical Trials More InclusiveBroadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.
by Ashley P. Taylor
-
What Do Clinical Trial Endpoints Really Measure?A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.
by Jon Kelvey
-
2018: This Year in Cancer NewsThe Cancer Today editorial staff selects some of the most interesting and impactful reporting, research and perspectives of 2018.
by Cancer Today Staff
-
2018 SABCS: Choosing the Right TreatmentStudies presented at the 2018 San Antonio Breast Cancer Symposium investigate when patients with early-stage breast cancer or precancerous breast conditions benefit from receiving less intense treatment.
by Kate Yandell
-
The Roots of Rural Health DisparitiesNew research shows that rural cancer patients have the same health outcomes as urban cancer patients so long as they are involved in a clinical trial.
by Cheryl Platzman Weinstock
-
Will Right to Try Increase Access to Experimental Treatments?The recently passed Right to Try Act is meant to provide patients with greater access to experimental therapies. Patient advocates are divided on whether the law will benefit patients.
by Marci A. Landsmann
-
Omitting ObesityMany cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.
by Cici Zhang
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
Challenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
